Influenza virus infection
Conditions
Interventions
Peramivir, Intravenously administration 600mg once a day, allowing daily injection if the patient condition is severe.
Oseltamivir, Orally administration, 75mg twice a day for 5 days.
Sponsors
Nagasaki evaluation organization for clinical interventions
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who satisfied below 1)-7): 1)Age:>=20 2)Agreement with documents 3)Fever>=38.0 degrees centigrade 4)>=2 items of ISS* which as moderate symptoms 5)Within 48hour after onset: Onset time is defined as below (1)First time at increase of body temperature (>=1 degrees centigrade as usual) (2)First time which the patient aware >=1 items of ISS* 6)Positive for Rapid Antigen Test kit 7)With at least one risk factor *ISS=Influenza Symptoms Severity
Exclusion criteria
Exclusion criteria: 1)contraindication of peramivir and oseltamivir 2)pregnant or probable pregnant women 3)Inappropriate judged by doctors 4)pneumonia on the 1st day of visiting hospital
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The duration of fever | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms of influenza infection, viral titer and subtype, complications, exacerbation of underlying diseases, H275Y mutation of the virus isolated from the patients with poor clinical effects, The detection of colonized pneumococcus in nasal pharynx in the patients complicated secondary bacterial pneumonia | — |
Countries
Japan
Contacts
Public ContactTaiga Miyazaki
Nagasaki evaluation organization for clinical interventions office
Outcome results
None listed